Every Form 4 that Turn Therapeutics Inc. (TTRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.
Turn Therapeutics director Martin William Dewhurst received a grant of stock options covering 71,666 shares of Common Stock at an exercise price of $5.75 per share. The options vest in twelve equal monthly installments beginning on June 30, 2026 and expire on June 4, 2036.
Following this award, he holds 71,666 stock options directly, all tied to continued employment and the terms of the 2025 Omnibus Incentive Plan.
Turn Therapeutics director Andrew Gengos received a grant of stock options covering 95,000 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments starting on June 30, 2026, contingent on his continued employment under the company’s 2025 Omnibus Incentive Plan. This is a compensation-related award, not an open-market share purchase or sale.
Turn Therapeutics Inc. director Arthur F. Golden received a grant of stock options for 89,584 shares of common stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036. They vest in twelve equal monthly installments beginning on June 30, 2026, contingent on continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this award, Golden holds 89,584 option-based rights directly.
Turn Therapeutics Inc. director Kester Kent Edward received a grant of stock options covering 83,334 shares of Common Stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036.
The option award vests in twelve equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this grant, the reporting person holds 83,334 stock options directly.
Turn Therapeutics Inc. director and Chief Executive Officer Bradley E. Burnam reported a series of bona fide gifts of the company’s common stock on May 28, 2026. The filing shows four gift transactions totaling 1,200,000 shares, each recorded at a price of $0.0000 per share, meaning no cash changed hands.
Part of the stock is held and transferred through BEB Holdings, LLC, where Burnam is the sole member with sole voting and dispositive power. Other portions were gifted to two 2026 revocable trusts established for his daughter and son. The filing states Burnam disclaims beneficial ownership of the shares held by these trusts for Section 16 and other purposes.
Turn Therapeutics Inc. director and Chief Executive Officer Burnam Bradley Evan reported a bona fide gift of 300,000 shares of common stock, carried out through BEB Holdings, LLC, an entity he solely controls. The gift involved no sale proceeds, with a reported price of $0.00 per share. Following this indirect disposition, BEB Holdings, LLC, which is deemed beneficially owned by Burnam Bradley Evan due to his sole voting and dispositive power, held 15,716,260 shares of Turn Therapeutics common stock.
Turn Therapeutics Inc. director Arthur F. Golden reported a bona fide gift of 300,000 shares of Common Stock. The shares were transferred at a reported price of $0.0000 per share, reflecting a non-market, no‑consideration disposition. Following the gift, he directly holds 360,602 Common Stock shares.
Turn Therapeutics Inc. reported that Chief Executive Officer and director Burnam Bradley Evan received an employee stock option grant covering 160,000 shares of common stock at an exercise price of $3.43 per share. The option was granted as compensation at no purchase price on the grant date.
According to the vesting terms, 25% of the option will vest on the first anniversary of the grant date, with the remaining 75% vesting in equal installments over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan.
Turn Therapeutics Inc. reported that officer Zuraiz Chaudhary received an award of 80,000 employee stock options on April 1, 2026. These options allow the purchase of common stock at an exercise price of $3.12 per share, with no cash paid at grant.
After this award, Chaudhary holds 80,000 stock options directly. The options vest over time: 25% vests on the first anniversary of the grant date and the remaining 75% vests ratably over the following 36 months, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. This is a compensation grant, not an open‑market share purchase or sale.
Turn Therapeutics Inc. director Martin William Dewhurst received an award of 21,882 restricted stock units (RSUs) of common stock on January 7, 2026 at a price of $0 per unit. Each RSU represents the right to receive one share of common stock.
The 21,882 RSUs vest in full on January 7, 2027, provided Dewhurst continues to serve the company through that date. The award was made under Turn Therapeutics’ 2025 Omnibus Incentive Plan and is held directly by the reporting person.
Turn Therapeutics Inc. reported an insider stock purchase by officer Zuraiz Chaudhary. On 12/12/2025, Chaudhary bought 2,500 shares of common stock at $3.5 per share, bringing their directly held beneficial ownership to 12,500 shares.
Chaudhary serves as Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer, and this report covers a single reporting person with direct ownership of the common stock.
Turn Therapeutics Inc. (TTRX) filed a Form 4 reporting a stock purchase by a director. On 11/24/2025, a reporting person serving as a director acquired 9,868 shares of Turn Therapeutics common stock in an open-market transaction coded "P" for purchase.
The weighted average purchase price was $3.44 per share, with individual trades executed between $3.25 and $3.50. Following this transaction, the reporting person beneficially owns 60,602 shares of Turn Therapeutics common stock, which includes restricted stock units granted under the company’s 2025 Omnibus Incentive Plan. Each RSU represents a right to receive one share of common stock, subject to vesting and continued service.
Turn Therapeutics Inc. (TTRX) reported an insider share purchase by a director. On 11/21/2025, the reporting person bought 20,532 shares of common stock in an open-market transaction at a weighted average price of $2.87 per share, with individual trades ranging from $2.66 to $3.25. After this transaction, the director beneficially owns 50,734 shares of common stock.
Certain shares in this total are restricted stock units (RSUs) granted under Turn Therapeutics’ 2025 Omnibus Incentive Plan, each RSU representing a right to receive one common share if vesting conditions and continued service requirements are satisfied.
Turn Therapeutics Inc. (TTRX) reported open-market stock purchases by its Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer. On 11/20/2025, the officer bought 1,450 shares of common stock at $2.61 per share, followed by another purchase of 1,000 shares at $3.29 per share on 11/21/2025. After these transactions, the officer beneficially owned 10,000 shares of Turn Therapeutics common stock, held directly.